Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
A phase 3 trial of Encorafenib, Binimetinib in melanoma, run by Pierre Fabre Medicament, active and no longer recruiting.
Overview
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. is a phase 3 interventional study registered as NCT05270044 by Pierre Fabre Medicament, with 815 participants planned, started 2022-05-02 and due to reach its primary completion in 2027-03-31. Interventions recorded: Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Binimetinib, Encorafenib, Melanoma.
- TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
Shares Binimetinib, Encorafenib.
- TrialCOLUMBUS
Shares Binimetinib, Encorafenib, Melanoma.
- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, Melanoma.
- TrialStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Shares Binimetinib, Melanoma.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Encorafenib, Melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Encorafenib, Melanoma.
- CompanyPierre Fabre
Shares Binimetinib, Encorafenib.